S
SinoTau
Integrated solutions in radiopharmaceutical R&D for early prevention, diagnosis, and treatment globally
About SinoTau
Sinotau Pharmaceutical Group, founded in 2005, focuses on providing integrated solutions for early prevention, diagnosis, and treatment of diseases through advanced radiopharmaceutical research and development (R&D). The company operates primarily in the healthcare sector, targeting both the Chinese market and international markets. Sinotau serves a diverse range of clients including hospitals, research institutions, and healthcare providers. Its business model revolves around the development, manufacturing, and distribution of radiopharmaceuticals, which are specialized drugs that contain radioactive substances used for diagnosis or treatment of diseases. The company generates revenue through the sale of these radiopharmaceutical products and by offering related services such as clinical academic promotion and quality manufacturing processes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2005
- Headquarters
- Changping District, China
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 45.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Jul 2023 | $151M | $605M | Guangdong Technology Financial Group · SDIC Venture Capital · Ennovation Ventures · Jimin Trust | ↗ |
| SERIES DOther financing | Oct 2021 | $44M | $176M | China Life Private Equity Investment · Centurium Capital | — |
Growth signals
Latest recorded traffic for SinoTau is 5.7K monthly website visits, up 338.5% over the last three months. SinoTau's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- WVWinning Ventures
Qiming Venture Partners
Series B and later25 investors entered at this stage
- H(Hetang Venture Capital Management (Beijing)
- SCSinopharm Capital
- GMGuoke Jiahe (Beijing) Investment Management
CICC- LCLongmen Capital
Everest Venture Capital- DIDeyi Investment
- CIChina Life Private Equity Investment
Centurium Capital
Guangdong Technology Financial Group
SDIC Venture Capital- EVEnnovation Ventures
- JTJimin Trust
- QZQing Shi Zhenhe
- CCChengming Capital
CITIC Securities
China Structural Reform Fund
CITIC Gold Stone Investment
GF Qianhe- GFGage Finance
SDIC Chuangyi- XIXinshang Investment
- ZCZhongshan Venture Capital
- ZIZhizhong Investment
- LCLide Measurement and Control
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SinoTau on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SinoTau’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.